Related Experiment Video
Updated: May 26, 2026
Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts
Published on: December 22, 2015
Can we build a better allograft?
1The Ohio State University Comprehensive Cancer Center.
Abstract:
Compelling evidence has been accumulating recently implicating disruption of CXCR4/CXCL12 signaling as a key step in the mobilization of hematopoietic stem and progenitor cells (HSPCs) induced by G-CSF and other agents. This knowledge formed the rationale for the clinical development and ultimate FDA approval of a specific CXCR4 antagonist, AMD3100, for the mobilization of HSPCs in patients with non-Hodgkin lymphoma and multiple myeloma when given in combination of G-CSF.
Insights
Disrupting CXCR4/CXCL12 signaling mobilizes hematopoietic stem and progenitor cells (HSPCs). This led to the FDA approval of AMD3100 for HSPC mobilization in lymphoma and myeloma patients treated with G-CSF.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Disruption of the CXCR4/CXCL12 signaling pathway is implicated in hematopoietic stem and progenitor cell (HSPC) mobilization.
- Granulocyte-colony stimulating factor (G-CSF) and other agents induce HSPC mobilization, partly through this pathway.
Discussion:
- The CXCR4 antagonist AMD3100 targets this critical signaling pathway.
- AMD3100's mechanism of action is crucial for its efficacy in HSPC mobilization.
Key Insights:
- AMD3100 (plerixafor) is FDA-approved for HSPC mobilization.
- This drug is used in combination with G-CSF for specific hematologic malignancies.
Outlook:
- Further research may explore AMD3100 in other contexts or with novel agents.
- Understanding CXCR4/CXCL12 signaling continues to advance stem cell mobilization strategies.
More Related Videos
09:36Modified Heterotopic Hindlimb Osteomyocutaneous Flap Model in the Rat for Translational Vascularized Composite Allotransplantation Research
Published on: April 26, 2019
10:31Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
Published on: August 13, 2017